Skip to main content

Table 5 In-hospital and 30 days outcomes after TAVR procedure

From: Percutaneous treatment of abdominal aortic aneurysm and aortic valve stenosis with ‘staged’ EVAR and TAVR: a case series

Case

Device success

Post-procedural TTE transvalvular gradient peak/mean (mmHg)

PVL

LVEF (%)

Major Vascular complication VARC-2y

Femoral hematoma pseudoaneurysm

Permanent pacemaker implantation

Stroke/TIA

Periprocedural MI

Unplanned intra-procedural PCI

Stage 2 or 3 Acute kidney injury

Bleeding (BARC)

Hospitalization lenght (days)*

30 days mortaliy

1

Yes

15/9

Mild

55

No

No

No

No

No

No

No

No

13

No

2

Yes

14/7

No

55

Yes

Yes

No

No

No

No

No

No

5

No

3

Yes

16/7

Mild

45

No

No

No

No

No

No

No

No

7

No

4

Yes

20/11

No

60

No

No

Yes

No

No

No

No

No

6

No

5

Yes

18/10

No

39

No

No

No

No

No

No

No

No

4

No

  1. BARC bleeding academy research consortium, LVEF left ventricle ejection fraction, PVL paravalvular leak, TIA transient ischemic attack, VARC vascular academy research consortium
  2. *Length of stay was calculated from TAVR procedure (day 0) to day of discharge